Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15138186 | 0.76 | ATM (0.65) | ATMMMEALDH1A1MEN1KMT2A | |
| SCHEMBL30206032 | 0.76 | ATM (0.65) | ATMMMEALDH1A1MEN1KMT2A | |
| SCHEMBL12368660 | 0.76 | ATM (0.65) | ATMMMEALDH1A1MEN1KMT2A | |
| SCHEMBL31759050 | 0.76 | ATM (0.65) | ATMMMEALDH1A1MEN1KMT2A | |
| SCHEMBL3272065 | 0.76 | ATM (0.65) | ATMMMEALDH1A1MEN1KMT2A | |
| SCHEMBL31707416 | 0.76 | ATM (0.65) | ATMMMEALDH1A1MEN1KMT2A | |
| SCHEMBL12820517 | 0.75 | ALDH1A1 (0.54) | ALDH1A1ACE | |
| SCHEMBL13227714 | 0.74 | CYP1A2 (0.46) | ATMALDH1A1EPHX1 | |
| SCHEMBL30070929 | 0.73 | ATM (0.61) | ATMMMEALDH1A1MEN1KMT2A | |
| SCHEMBL19859070 | 0.73 | ATM (0.70) | ATMMMEALDH1A1ACEPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477980-B1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2016-06-08 | — | — | EP | disclosed |
| US-8389560-B2 | HCV protease inhibitors | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2013-03-05 | — | — | US | disclosed |
| US-8389560-B2 | HCV protease inhibitors | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2013-03-05 | — | — | US | disclosed |
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2011-03-17 | — | — | US | disclosed |
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | RNASE1, HAVCR2, CTRL | ATM 4636/4885MME 76/4885ALDH1A1 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.